Shots: The NMPA’s approval is based on P-III PINNACLE 4 study assessing Bevespi Aerosphere (bid via a pMDI) vs its monotherapy components (glycopyrronium and formoterol fumarate) and PBO in patients […]readmore
Shots: The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6mcg) vs Bevespi Aerosphere (glycopyrronium/formoterol fumarate 14.4/9.6mcg) and PT009 (budesonide/formoterol fumarate 320/9.6mcg) in symptomatic patients with mod. to sev. COPD […]readmore
Shots: The approval of Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate) is based on P-III KRONOS study results assessing PT010 vs Bevespi Aerosphere & PT009 in patients with COPD, resulted in improvement […]readmore
Shots: The AERISTO study recruited 1,119 patients receiving either Bevespi Aerosphere (7.2/4.8µg) BID via pressurized metered-dose inhaler or umeclidinium/vilanterol (62.5/25µg) QD via dry powder inhaler Another P-III PINNACLE study enrolled […]readmore
Copyright © 2020 Digiqole. All Right Reserved.